dasatinib + docetaxel

Dasatinib + docetaxel is a combination regimen of the oral multi-kinase inhibitor **dasatinib** and the intravenous antineoplastic agent **docetaxel**. Dasatinib targets multiple tyrosine kinases, most notably **SRC family kinases**, BCR-ABL, c-KIT, EPHA2, EGFR, and PDGF receptors, thereby inhibiting tumor cell proliferation and affecting the tumor microenvironment, including bone turnover. Docetaxel is a microtubule stabilizing agent that inhibits cell division by binding to and stabilizing tubulin, inducing apoptosis in rapidly dividing cells. This combination has been explored especially in metastatic castration-resistant prostate cancer (mCRPC) and various solid tumor preclinical models, aiming to achieve synergistic antitumor effects by targeting tumor cells and the tumor microenvironment. While early-phase studies showed some synergistic activity and acceptable safety, phase 3 clinical trial data failed to demonstrate improved overall survival relative to docetaxel alone in mCRPC. The combination has also been explored preclinically in uterine leiomyosarcoma and other cancers[1][2][3][4].